Antibody variable region engineering for improving cancer immunotherapy

Cancer Communications

article

Hantao Lou¹  Xuetao Cao² 

[1] Ludwig Institute of Cancer Research, University of Oxford;Chinese Academy for Medical Sciences Oxford Institute, Nuffield Department of Medicine, University of Oxford;Department of Immunology, Centre for Immunotherapy, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences

关键词: antibody engineering;    bi/trispecific killer engager;    cancer immunotherapy;    chimeric antigen receptor-T (CAR-T) cell;    nanobody;    natural killer (NK) cell;    scFv;   

DOI  :  10.1002/cac2.12330

学科分类：社会科学、人文和艺术（综合）

来源: Springer

【 摘 要 】

The efficacy and specificity of conventional monoclonal antibody (mAb) drugs in the clinic require further improvement. Currently, the development and application of novel antibody formats for improving cancer immunotherapy have attracted much attention. Variable region-retaining antibody fragments, such as antigen-binding fragment (Fab), single-chain variable fragment (scFv), bispecific antibody, and bi/trispecific cell engagers, are engineered with humanization, multivalent antibody construction, affinity optimization and antibody masking for targeting tumor cells and killer cells to improve antibody-based therapy potency, efficacy and specificity. In this review, we summarize the application of antibody variable region engineering and discuss the future direction of antibody engineering for improving cancer therapies.

【 授权许可】

CC BY|CC BY-NC-ND